Pharma Struggles To Escape FCPA Net

Law360, New York (November 23, 2010, 7:30 PM EST) -- The U.S. government’s Foreign Corrupt Practices Act investigation of the pharmaceutical industry exposes major drugmakers to untold risks and gives executives the Herculean task of controlling the way business is conducted in emerging markets by foreign nationals and other far-flung agents, according to experts in the field.

The U.S. Department of Justice has been vocal about ushering in a new era of FCPA enforcement, with the agency focused on the pharmaceutical and medical device industries, among others, in recent months. Pharmaceutical heavyweights like Merck & Co....
To view the full article, register now.